Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Down 64.1% in March

Vincerx Pharma, Inc. (NASDAQ:VINC) was the target of a large decline in short interest in the month of March. As of March 15th, there was short interest totalling 68,800 shares, a decline of 64.1% from the February 28th total of 191,900 shares. Currently, 3.6% of the company’s shares are short sold. Based on an average trading volume of 1,220,000 shares, the short-interest ratio is currently 0.1 days.

Vincerx Pharma Stock Performance

NASDAQ:VINC opened at $0.57 on Friday. Vincerx Pharma has a fifty-two week low of $0.49 and a fifty-two week high of $136.80. The company has a 50 day moving average price of $1.28 and a 200 day moving average price of $5.33. The stock has a market capitalization of $1.27 million, a P/E ratio of -0.03 and a beta of 1.43.

About Vincerx Pharma

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.